| Literature DB >> 26364633 |
Nadjet Rezki1,2, Amjad M Al-Yahyawi3, Sanaa K Bardaweel4, Fawzia F Al-Blewi5, Mohamed R Aouad6,7.
Abstract
In the present study, a new series of 2,5-disubstituted-1,3,4-thiadiazole tetheredEntities:
Keywords: 1,2,4-triazole; 1,3,4-oxadiazole; 1,3,4-thiadiazole; Schiff base; antimicrobial activity; antitumor activity
Mesh:
Substances:
Year: 2015 PMID: 26364633 PMCID: PMC6331880 DOI: 10.3390/molecules200916048
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of bis-acid thiosemicarbazides 4–6.
Scheme 2Synthesis of 1,2,4-triazoles 7–9, 1,3,4-thiadiazoles 10–12 and 1,3,4-oxadiazoles 13–15.
Scheme 3Synthesis of 1,3,4-oxadiazole derivatives 16–19.
Scheme 4Synthesis of 4-amino-1,2,4-triazole 20 and Schiff bases 21–26.
Antimicrobial activity expressed as MIC (μg/mL).
| Compound No. | Gram-Positive Organism a | Gram-Negative Organism b | Fungi c | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 31.25 | 31.25 | 31.35 | 16 | 31.25 | 16 | 31.25 | 62.5 | 31.25 | |
| 16 | 8 | 31.25 | 31.25 | 16 | 16 | 31.25 | 31.25 | 62.5 | |
| 16 | 31.25 | 31.25 | 31.25 | 31.25 | 16 | 62.5 | 31.25 | 62.5 | |
| 31.25 | 31.25 | 16 | 31.25 | 16 | 31.25 | 125 | 250 | 62.5 | |
| 31.25 | 16 | 16 | 31.25 | 31.25 | 16 | 125 | 250 | 125 | |
| 8 | 8 | 16 | 16 | 16 | 8 | 8 | 8 | 16 | |
| 16 | 31.25 | 16 | 31.25 | 31.25 | 16 | 16 | 16 | 31.25 | |
| 16 | 16 | 8 | 31.25 | 16 | 31.25 | 16 | 31.25 | 16 | |
| 8 | 16 | 16 | 31.25 | 16 | 16 | 16 | 16 | 8 | |
| 16 | 31.25 | 31.25 | 31.25 | 31.25 | 16 | 31.25 | 16 | 16 | |
| 16 | 16 | 31.25 | 16 | 16 | 31.25 | 16 | 16 | 8 | |
| 8 | 8 | 16 | 62.5 | 62.5 | 31.25 | 31.25 | 31.25 | 62.5 | |
| 16 | 16 | 16 | 31.25 | 125 | 62.5 | 31.25 | 62.5 | 62.5 | |
| 8 | 16 | 8 | 31.25 | 62.5 | 31.25 | 62.5 | 31.25 | 31.25 | |
| 4 | 8 | 4 | 4 | 8 | 8 | 31.25 | 16 | 16 | |
| 16 | 8 | 16 | 16 | 8 | 16 | 31.25 | 16 | 16 | |
| 16 | 16 | 16 | 16 | 16 | 8 | 31.25 | 16 | 16 | |
| 16 | 16 | 8 | 16 | 16 | 16 | 31.25 | 16 | 16 | |
| 4 | 4 | 8 | 8 | 4 | 4 | 16 | 16 | 8 | |
| 16 | 8 | 16 | 16 | 8 | 16 | 31.25 | 16 | 16 | |
| 8 | 8 | 8 | 16 | 8 | 16 | 31.25 | 16 | 16 | |
| 8 | 8 | 4 | 8 | 4 | 8 | 31.25 | 16 | 16 | |
| 8 | 4 | 4 | 8 | 4 | 8 | 31.25 | 31.25 | 16 | |
| 8 | 8 | 16 | 8 | 16 | 8 | 16 | 16 | 31.25 | |
| 8 | 16 | 8 | 8 | 8 | 16 | 31.25 | 16 | 16 | |
| Ciprofloxacin | ≤5 | ≤1 | ≤5 | ≤5 | ≤1 | ≤1 | - | - | - |
| Fluconazole | - | - | - | - | - | - | ≤1 | ≤1 | ≤1 |
a Gram-positive bacteria: Streptococcus pneumonia, Bacillus subtilis, Staphylococcus aureus; b Gram-negative bacteria: Pseudomonas aeuroginosa, Escherichia coli, Klebsiella pneumonia; c yeasts: Aspergillus fumigatus, Candida albicans, Geotrichum candidum.
The LD50 values (ng/μL) of the examined compounds on four human cancer cell lines. Values are expressed as mean ± SD of three experiments.
| Compound No. | MCF-7 | T47D | Caco II | HeLa |
|---|---|---|---|---|
| 376± 16 | 389 ± 12 | 387 ± 8 | 391 ± 10 | |
| 409± 9 | 418± 10 | 418 ± 9 | 438 ± 9 | |
| 673 ± 15 | 648 ± 11 | 668 ± 19 | 690 ± 17 | |
| 398 ± 10 | 397 ± 9 | 373 ± 10 | 356 ± 12 | |
| 519 ± 11 | 527 ± 19 | 502 ± 17 | 498 ± 23 | |
| 863 ± 12 | 798 ± 18 | 678 ± 11 | 562 ± 8 |
Human breast adenocarcinoma MCF7, Human ductal breast epithelial tumor T47D, Human epithelial colorectal adenocarcinoma Caco II and Human epithelial carcinoma HeLa.